Tilray Medical, a division of Tilray Brands Inc., has received authorization from Italy’s Ministry of Health to import and distribute three varieties of medical cannabis flower for therapeutic use. This marks the first time a company has been granted such permission in Italy.
Beginning this month, patients in Italy can access Tilray’s medical cannabis products through pharmacies. The approved strains include: – Tilray THC 25% – Tilray THC 18% – Tilray THC 9% / CBD 9%
Denise Faltischek, Chief Strategy Officer at Tilray Brands, emphasized the importance of medical cannabis in patient care. She stated that this achievement allows Tilray to expand its portfolio in Italy with high-quality, EU-GMP certified products, which adhere to strict standards for safety and efficacy.
Tilray’s operation in Italy is part of a broader strategy to lead the European medical cannabis market. The company already has established operations in Germany, Portugal, Poland, and the United Kingdom, providing a wide range of EU-GMP certified medical cannabis products.
The Italian Ministry of Health’s decision to authorize the distribution of Tilray’s cannabis flower is a significant step toward improving access to cannabinoid-based therapies in the country. This regulatory framework aims to ensure that patients receive safe and consistent treatment options.
Tilray’s entry into the Italian market not only signifies a growth opportunity for the company but also reflects the increasing acceptance of medical cannabis across Europe. As more countries recognize the therapeutic potential of cannabis, companies like Tilray are poised to play a key role in shaping the future of medical cannabis in the region.
Spanish 
English 
German 
Czech